Michela Semeraro1, Elisa Sacchetti2, Federica Deodato2, Turgay Coşkun3, Incilay Lay4, Giulio Catesini2, Giorgia Olivieri2, Cristiano Rizzo2, Sara Boenzi2, Carlo Dionisi-Vici2. 1. Division of Metabolism and Metabolic Diseases Research Unit, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy. michela.semeraro@opbg.net. 2. Division of Metabolism and Metabolic Diseases Research Unit, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy. 3. Metabolism Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey. 4. Department of Medical Biochemistry and Hacettepe University Hospitals Clinical Pathology Laboratory, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Abstract
BACKGROUND: Oligosaccharidoses are storage disorders due to enzymatic defects involved in the breakdown of the oligosaccharidic component of glycosylated proteins. The defect cause the accumulation of oligosaccharides (OS) and, depending on the lacking enzyme, results in characteristic profiles which are helpful for the diagnosis. We developed a new tandem mass spectrometry method for the screening of urinary OS which was applied to identify a large panel of storage disorders. METHODS: The method was set-up in urine and dried urine spots (DUS). Samples were analysed, without derivatization and using maltoheptaose as internal standard, by UHPLC-MS/MS with MRM acquisition of target OS transitions, including Glc4, the biomarker of Pompe disease. The chromatographic run was < 30 min. Samples from patients with known storage disorders were used for clinical validation. RESULTS: The method allowed to confirm the diagnosis of oligosaccharidoses (sialidosis, α-/β-mannosidosis, fucosidosis, aspartylglucosaminuria) and of GM1 and GM2 (Sandhoff type) gangliosidosis, by detecting specific OS profiles. In other storage disorders (mucolipidosis II and III, mucopolysaccharidosis type IVB) the analyisis revealed abnormal OS excretion with non-specific profiles. Besides Pompe disease, the tetrasaccharide Glc4 was increased also in disorders of autophagy (Vici syndrome, Yunis-Varon syndrome, and Danon disease) presenting cardiomuscular involvement with glycogen storage. Overall, results showed a clear separation between patients and controls, both in urine and in DUS. CONCLUSION: This new UHPLC/MS-MS method, which is suitable for rapid and easy screening of OS in urine and DUS, expands the detection of storage disorders from oligosaccharidoses to other diseases, including the novel category of inherited disorders of autophagy.
BACKGROUND: Oligosaccharidoses are storage disorders due to enzymatic defects involved in the breakdown of the oligosaccharidic component of glycosylated proteins. The defect cause the accumulation of oligosaccharides (OS) and, depending on the lacking enzyme, results in characteristic profiles which are helpful for the diagnosis. We developed a new tandem mass spectrometry method for the screening of urinary OS which was applied to identify a large panel of storage disorders. METHODS: The method was set-up in urine and dried urine spots (DUS). Samples were analysed, without derivatization and using maltoheptaose as internal standard, by UHPLC-MS/MS with MRM acquisition of target OS transitions, including Glc4, the biomarker of Pompe disease. The chromatographic run was < 30 min. Samples from patients with known storage disorders were used for clinical validation. RESULTS: The method allowed to confirm the diagnosis of oligosaccharidoses (sialidosis, α-/β-mannosidosis, fucosidosis, aspartylglucosaminuria) and of GM1 and GM2 (Sandhoff type) gangliosidosis, by detecting specific OS profiles. In other storage disorders (mucolipidosis II and III, mucopolysaccharidosis type IVB) the analyisis revealed abnormal OS excretion with non-specific profiles. Besides Pompe disease, the tetrasaccharideGlc4 was increased also in disorders of autophagy (Vici syndrome, Yunis-Varon syndrome, and Danon disease) presenting cardiomuscular involvement with glycogen storage. Overall, results showed a clear separation between patients and controls, both in urine and in DUS. CONCLUSION: This new UHPLC/MS-MS method, which is suitable for rapid and easy screening of OS in urine and DUS, expands the detection of storage disorders from oligosaccharidoses to other diseases, including the novel category of inherited disorders of autophagy.
Authors: Sarah P Young; Monique Piraud; Jennifer L Goldstein; Haoyue Zhang; Catherine Rehder; Pascal Laforet; Priya S Kishnani; David S Millington; Mustafa R Bashir; Deeksha S Bali Journal: Am J Med Genet C Semin Med Genet Date: 2012-01-17 Impact factor: 3.908
Authors: F Dworzak; M Mora; C Borroni; F Cornelio; F Blasevich; A Cappellini; F Tagliavini; B Bertagnolio Journal: Neuromuscul Disord Date: 1995-09 Impact factor: 4.296
Authors: Steven L Ramsay; Irene Maire; Colleen Bindloss; Maria Fuller; Phillip D Whitfield; Monique Piraud; John J Hopwood; Peter J Meikle Journal: Mol Genet Metab Date: 2004-11 Impact factor: 4.797
Authors: Thomas Cullup; Ay Lin Kho; Carlo Dionisi-Vici; Birgit Brandmeier; Frances Smith; Zoe Urry; Michael A Simpson; Shu Yau; Enrico Bertini; Verity McClelland; Mohammed Al-Owain; Stefan Koelker; Christian Koerner; Georg F Hoffmann; Frits A Wijburg; Amber E ten Hoedt; R Curtis Rogers; David Manchester; Rie Miyata; Masaharu Hayashi; Elizabeth Said; Doriette Soler; Peter M Kroisel; Christian Windpassinger; Francis M Filloux; Salwa Al-Kaabi; Jozef Hertecant; Miguel Del Campo; Stefan Buk; Istvan Bodi; Hans-Hilmar Goebel; Caroline A Sewry; Stephen Abbs; Shehla Mohammed; Dragana Josifova; Mathias Gautel; Heinz Jungbluth Journal: Nat Genet Date: 2012-12-09 Impact factor: 38.330